ThecaFlex DRx is an investigational implantable device to deliver antisense oligonucleotides (ASOs) intrathecally. The device administers medicines to patients with neurologic disorders. It is designed to offer an
This authorisation is specifically for patients who have symptomatic TGCT, with significant physical functional decline, and for whom surgical intervention is either not an option or would lead
The investment round was jointly spearheaded by Qiming Venture Partners USA and Versant Ventures. It also saw contributions from SV Health Investors, the company’s founding investor, and new
The funds will help YolTech in advancing its clinical programmes and global strategic execution. Established in 2021, YolTech Therapeutics is stated to be advancing next-generation in vivo gene-editing
Turbine noted that laboratory models often fail to capture the molecular diversity and biological complexity of many solid tumours found in patients. This limitation hampers the development of
Osteoarthritis is a degenerative condition impacting more than 30 million adults in the US. This collaboration will focus on the promotion of Zilretta (triamcinolone acetonide extended-release injectable suspension),
The company completed a positive Phase IIa trial of the candidate for chronic subjects with peripheral neuropathic pain. It is now preparing for further clinical development and has
The new facility is claimed to enhance Biosynth’s ability to manufacture GMP bioconjugates, supporting the production of intermediates and active pharmaceutical ingredients from early clinical stages till late-phase
Bioeq is also the exclusive holder of the global commercialisation rights for the medicine, Formycon’s biosimilar candidate for Lucentis (ranibizumab). This agreement allows Bio Usawa to register and
The move is said to bolster the company’s North America and Europe presence, meeting the worldwide demand for critical injectable therapeutics. This expansion has enlarged the total production
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.